NLRP3 and ganglioneuroma: These findings demonstrate that ACP-60, particularly at high doses, effectively inhibits the NLRP3/ASC/Caspase-1 signaling pathway, highlighting its therapeutic potential in reducing inflammation and alleviating kidney damage in GN.